1. Abd El-Kader SM, El-Den Ashmawy EMS. Non-alcoholic fatty liver disease: The diagnosis and management. World J Hepatol. 2015;7(6):846-58.
2. Sherif ZA, Saeed A, Ghavimi S, Nouraie S-M, Laiyemo AO, Brim H, et al. Global Epidemiology of Nonalcoholic Fatty Liver Disease and Perspectives on US Minority Populations. Dig Dis Sci. 2016;61(5):1214-25.
3. Qiu S, Cai X, Sun Z, Li L, Zügel M, Steinacker JM, et al. Association between physical activity and risk of nonalcoholic fatty liver disease: a meta-analysis. Therap Adv Gastroenterol. 2017;10(9):701-13.
4. van der Windt DJ, Sud V, Zhang H, Tsung A, Huang H. The Effects of Physical Exercise on Fatty Liver Disease. Gene Expr. 2018;18(2):89-101.
5. Carneros D, López-Lluch G, Bustos M. Physiopathology of Lifestyle Interventions in Non-Alcoholic Fatty Liver Disease (NAFLD). Nutrients. 2020;12(11):3472.
6. Martínez-Garza Ú, Torres-Oteros D, Yarritu-Gallego A, Marrero PF, Haro D, Relat J. Fibroblast Growth Factor 21 and the Adaptive Response to Nutritional Challenges. Int J Mol Sci. 2019;20(19):4692.
7. Flisiak-Jackiewicz M, Bobrus-Chociej A, Wasilewska N, Tarasow E, Wojtkowska M, Lebensztejn DM. Can hepatokines be regarded as novel non-invasive serum biomarkers of intrahepatic lipid content in obese children? Adv Med Sci. 2019;64(2):280-4.
8. Barb D, Bril F, Kalavalapalli S, Cusi K. Plasma Fibroblast Growth Factor 21 Is Associated With Severity of Nonalcoholic Steatohepatitis in Patients With Obesity and Type 2 Diabetes. J Clin Endocrinol Metab. 2019;104(8):3327-36.
9. Haukeland JW, Dahl TB, Yndestad A, Gladhaug IP, Løberg EM, Haaland T, et al. Fetuin A in nonalcoholic fatty liver disease: in vivo and in vitro studies. Eur J Endocrinol. 2012;166(3):503-10.
10. Sanyal D, Mukherjee P, Raychaudhuri M, Ghosh S, Mukherjee S, Chowdhury S. Profile of liver enzymes in non-alcoholic fatty liver disease in patients with impaired glucose tolerance and newly detected untreated type 2 diabetes. Indian J Endocrinol Metab. 2015;19(5):597-601.
11. Mandal A, Bhattarai B, Kafle P, Khalid M, Jonnadula SK, Lamicchane J, et al. Elevated Liver Enzymes in Patients with Type 2 Diabetes Mellitus and Non-alcoholic Fatty Liver Disease. Cureus. 2018;10(11):e3626.
12. Thoma C, Day CP, Trenell MI. Lifestyle interventions for the treatment of non-alcoholic fatty liver disease in adults: a systematic review. J Hepatol. 2012;56(1):255-66.
13. Zouhal H, Zare-Kookandeh N, Haghighi MM, Daraei A, de Sousa M, Soltani M, et al. Physical activity and adipokine levels in individuals with type 2 diabetes: A literature review and practical applications. Rev Endocr Metab Disord. 2021.
14. Saeidi A, Haghighi MM, Kolahdouzi S, Daraei A, Abderrahmane AB, Essop MF, et al. The effects of physical activity on adipokines in individuals with overweight/obesity across the lifespan: A narrative review. Obes Rev. 2021;22(1):e13090.
15. Nathanson V. Revising the declaration of Helsinki. British Medical Journal Publishing Group; 2013.
16. Bredin SSD, Gledhill N, Jamnik VK, Warburton DER. PAR-Q+ and ePARmed-X+: new risk stratification and physical activity clearance strategy for physicians and patients alike. Can Fam Physician. 2013;59(3):273-7.
17. Borg G. Perceived exertion as an indicator of somatic stress. Scandinavian journal of rehabilitation medicine. 1970.
18. Pescatello LS, Riebe D, Thompson PD. ACSM's guidelines for exercise testing and prescription: Lippincott Williams & Wilkins; 2014.
19. Wallace TM, Levy JC, Matthews DR. Use and abuse of HOMA modeling. Diabetes Care. 2004;27(6):1487-95.
20. Dogru T, Kirik A, Gurel H, Rizvi AA, Rizzo M, Sonmez A. The Evolving Role of Fetuin-A in Nonalcoholic Fatty Liver Disease: An Overview from Liver to the Heart. Int J Mol Sci. 2021;22(12):6627.
21. Sakr HF, Al-Hashem FH, El-Naby WM, Alkhateeb MA, Zaki MS, Refaey HM, et al. Preventive roles of swimming exercise and pioglitazone treatment on hepatic dysfunction in a rat model of metabolic syndrome. Can J Physiol Pharmacol. 2014;92(2):162-70.
22. Malin SK, Mulya A, Fealy CE, Haus JM, Pagadala MR, Scelsi AR, et al. Fetuin-A is linked to improved glucose tolerance after short-term exercise training in nonalcoholic fatty liver disease. J Appl Physiol (1985). 2013;115(7):988-94.
23. Lee S, Norheim F, Gulseth HL, Langleite TM, Kolnes KJ, Tangen DS, et al. Interaction between plasma fetuin‐A and free fatty acids predicts changes in insulin sensitivity in response to long‐term exercise. Physiol Rep. 2017;5(5):e13183.
24. Glass OK, Radia A, Kraus WE, Abdelmalek MF. Exercise training as treatment of nonalcoholic fatty liver disease. Journal of Functional Morphology and Kinesiology. 2017;2(4):35.
25. Willis SA, Sargeant JA, Thackray AE, Yates T, Stensel DJ, Aithal GP, et al. Effect of exercise intensity on circulating hepatokine concentrations in healthy men. Applied Physiology, Nutrition, and Metabolism. 2019;44(10):1065-72.
26. Cuevas-Ramos D, Almeda-Valdés P, Meza-Arana CE, Brito-Córdova G, Gómez-Pérez FJ, Mehta R, et al. Exercise increases serum fibroblast growth factor 21 (FGF21) levels. PLoS One. 2012;7(5):e38022-e.
27. Kim KH, Jeong YT, Kim SH, Jung HS, Park KS, Lee HY, et al. Metformin-induced inhibition of the mitochondrial respiratory chain increases FGF21 expression via ATF4 activation. Biochem Biophys Res Commun. 2013;440(1):76-81.
28. Kim KH, Kim SH, Min Y-K, Yang H-M, Lee J-B, Lee M-S. Acute exercise induces FGF21 expression in mice and in healthy humans. PLoS One. 2013;8(5):e63517-e.
29. Smart NA, King N, McFarlane JR, Graham PL, Dieberg G. Effect of exercise training on liver function in adults who are overweight or exhibit fatty liver disease: a systematic review and meta-analysis. British Journal of Sports Medicine. 2018;52(13):834.
30. Shamsoddini A, Sobhani V, Ghamar Chehreh ME, Alavian SM, Zaree A. Effect of Aerobic and Resistance Exercise Training on Liver Enzymes and Hepatic Fat in Iranian Men With Nonalcoholic Fatty Liver Disease. Hepat Mon. 2015;15(10):e31434-e.
31. Sreenivasa Baba C, Alexander G, Kalyani B, Pandey R, Rastogi S, Pandey A, et al. Effect of exercise and dietary modification on serum aminotransferase levels in patients with nonalcoholic steatohepatitis. J Gastroenterol Hepatol. 2006;21(1 Pt 1):191-8.